...
首页> 外文期刊>Diabetes >Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program
【24h】

Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program

机译:基于34个确诊的2型糖尿病基因座的最新遗传评分与糖尿病的发病率以及糖尿病预防计划中降血糖的相关性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective-over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (grss) developed from these loci predict diabetes in the general population. We tested if a grs based on an updated list of 34 type 2 diabetes-associated loci predicted progression to diabetes or regression toward normal glucose regulation (ngr) in the diabetes prevention program (dpp). Research design and methods-we genotyped 34 type 2 diabetes-associated variants in 2,843 dpp participants at high risk of type 2 diabetes from five ethnic groups representative of the u.s. population, who had been randomized to placebo, metformin, or lifestyle intervention. We built a grs by weighting each risk allele by its reported effect size on type 2 diabetes risk and summing these values. We tested its ability to predict diabetes incidence or regression to ngr in models adjusted for age, sex, ethnicity, waist circumference, and treatment assignment. Results-in multivariate-adjusted models, the grs was significantly associated with increased risk of progression to diabetes (hazard ratio [hr] = 1.02 per risk allele [95% ci 1.00-1.05]; p = 0.03) and a lower probability of regression to ngr (hr = 0.95 per risk allele [95% ci 0.93-0.98]; p < 0.0001). At baseline, a higher grs was associated with a lower insulinogenic index (p < 0.001), confirming an impairment in p-cell function. We detected no significant interaction between grs and treatment, but the lifestyle intervention was effective in the highest quartile of grs (p < 0.0001). Conclusions-a high grs is associated with increased risk of developing diabetes and lower probability of returning to ngr in high-risk individuals, but a lifestyle intervention attenuates this risk. Diabetes 60:1340-1348, 2011
机译:在全基因组统计意义上,超过30个基因座的目标与2型糖尿病风险相关。从这些基因座得出的遗传风险评分(grss)可预测普通人群中的糖尿病。我们测试了基于34个2型糖尿病相关位点的更新列表的grs是否在糖尿病预防计划(dpp)中预测了糖尿病的进展或向正常葡萄糖调节(ngr)的回归。研究设计和方法-我们对来自美国五个种族的2,843 dpp高风险2型糖尿病参与者中的34个2型糖尿病相关变体进行了基因分型。人群,已被随机接受安慰剂,二甲双胍或生活方式干预。我们通过根据每个风险等位基因报告的对2型糖尿病风险的影响大小对每个风险等位基因进行加权,然后将这些值相加来构建一个grs。我们在针对年龄,性别,种族,腰围和治疗分配调整的模型中测试了其预测糖尿病发病率或回归到ngr的能力。在多元调整模型中,结果显示,grs与患糖尿病的风险增加显着相关(风险比[hr] = 1.02 /每风险等位基因[95%ci 1.00-1.05]; p = 0.03)和降低的回归概率到ngr(hr = 0.95每个风险等位基因[95%ci 0.93-0.98]; p <0.0001)。在基线时,较高的grs与较低的致胰岛素指数相关(p <0.001),证实了p细胞功能受损。我们没有发现grs和治疗之间存在显着的相互作用,但是生活方式干预对grs的最高四分位数有效(p <0.0001)。结论-高grs与高风险个体罹患糖尿病的风险增加和降低返回ngr的可能性有关,但是生活方式干预可以降低这种风险。糖尿病60:1340-1348,2011年

著录项

  • 来源
    《Diabetes》 |2011年第4期|p.1340-1348|共9页
  • 作者单位

    Division of Endocrinology, Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada;

    The Biostatistics Center, The George Washington University, Rockville, Maryland;

    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado at Denver School of Medicine, Aurora, Colorado;

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts,Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts;

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts,Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts;

    Department of Public Health and Clinical Medicine, Division of Medicine, Genetic Epidemiology and Clinical Research Group, Umea University Hospital, Umea, Sweden,Department of Clinical Sciences, Lund University Diabetes Center, Lund University, Malmo, Sweden;

    Department of Epidemiology, Colorado School of Public Health, University of Colorado at Denver, Aurora, Colorado;

    Division of Metabolism, Endocrinology and Nutrition, Veterans' Affairs Puget Sound Health Care System and the University of Washington, Seattle, Washington;

    Baylor College of Medicine, Houston, Texas;

    General Medicine Unit, Massachusetts General Hospital, Boston, Massachusetts,Department of Medicine, Harvard Medical School, Boston, Massachusetts;

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts,Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts,Department of Medicine, Harvard Medical School, Boston, Massachusetts,Department of Genetics, Harvard Medical School, Boston, Massachusetts,Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts;

    Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona;

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts,Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts,Department of Medicine, Harvard Medical School, Boston, Massachusetts,Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号